Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Universal Donor TGFβi NK Cells

Cell therapy (NK cells) · Kills target cells

Phase 2 Most advanced trial
1 Registered trials

What is Universal Donor TGFβi NK Cells?

Universal Donor TGFβi NK Cells are natural killer cells engineered outside the body and given by infusion at 1x10^8 cells/kg per treatment cycle.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (NK cells)
Mechanism
Kills target cells
Therapy area
Oncology
In trials of
UTHR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06450041 Phase 2 Neuroblastoma Recruiting UTHR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neuroblastoma

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.